Results of two new studies sponsored by the National Institute of Allergy and Infectious Diseases (NIAID), a component of the National Institutes of Health (NIH), suggest that even if an HIV vaccine offers imperfect protection against the virus, it might provide vaccinated individuals with an important benefit: a significant survival advantage after infection.
